Skip to main content
. 2007 Spring;12(1):48–50.

TABLE 2.

Comparision of major adverse cardiac events between two groups

Atorvastatin (n=327) Control (n=321) P
Myocardial infarction*, n (%) 20 (6.4) 39 (12.3) 0.013
Revascularization, n (%) 60 (19.2) 84 (26.6) 0.029
All-cause death, n (%) 16 (5.1) 25 (7.9) 0.196
Combined end points, n (%) 84 (26.9) 131 (41.5) <0.001
*

Including fatal and nonfatal myocardial infarction